Acute coronary syndrome in the oncology patient: An avoidable event?

Saif, 2009, Fluoropyrimidine-associated cardiotoxicity: revisited, Expert Opin Drug Saf, 8, 191, 10.1517/14740330902733961 Deboever, 2013, Alternative treatment options in colorectal cancer patients with 5-fluorouracil- or capecitabine-induced cardiotoxicity, Clinical Colorectal Cancer, 12, 8, 10.1016/j.clcc.2012.09.003 Tsavaris, 2002, Cardiotoxicity following different doses and schedules of 5-fluorouracil administration for malignancy – a survey of 427 patients, Med Sci Monit, 8, 51 Meydan, 2005, Cardiotoxicity of de Gramont's regimen: incidence, clinical characteristics and long-term follow-up, Jpn J Clin Oncol, 35, 265, 10.1093/jjco/hyi071 Schoeber, 1993, Cardiotoxicity of 5-fluorouracil in combination with folinic acid in patients with gastrointestinal cancer, Cancer, 72, 2242, 10.1002/1097-0142(19931001)72:7<2242::AID-CNCR2820720730>3.0.CO;2-E Kosmas, 2008, Cardiotoxicity of fluoropyrimidines in different schedules of administration: a prospective study, J Cancer Res Clin Oncol, 134, 75, 10.1007/s00432-007-0250-9 Labianca, 1982, Cardiac toxicity of 5-fluorouracil: a study on 1083 patients, Tumori, 68, 505, 10.1177/030089168206800609 Sorrentino, 2012, 5-fluorouracil induced cardiotoxicity: review of the literature, Cardiol J, 19, 453, 10.5603/CJ.2012.0084 de Forni, 1992, Cardiotoxicity of high-dose continuous infusion fluorouracil: a prospective clinical study, J Clin Oncol, 10, 1795, 10.1200/JCO.1992.10.11.1795 Rezkalla, 1989, Continuous ambulatory ECG monitoring during fluorouracil therapy: a prospective study, J Clin Oncol, 7, 509, 10.1200/JCO.1989.7.4.509 Fontanella, 2014, Capecitabine-induced cardiotoxicity: more evidence or clinical approaches to protect the patients’ heart?, Onco Targets Ther, 7, 1783 Conti, 2012, Silent ischemia: clinical relevance, J Am Coll Cardiol, 59, 435, 10.1016/j.jacc.2011.07.050 Piepoli, 2016, Eur Heart J, 37, 2315, 10.1093/eurheartj/ehw106